摘要
钠-葡萄糖协同转运蛋白(SGLT)抑制剂是治疗2型糖尿病的新型药物,简介SGLT抑制剂的作用机制和研发现状,重点分析SGLT抑制剂在中国的专利申请量、申请人、技术领域、重点公司等。通过比较国外申请人和国内申请人在专利技术方面的优势和劣势,为国内SGLT抑制剂的深入开发提供参考。
SGLT inhibitors are novel medicines fur treating type 2 diabetes. The acting mechanisnas and current development of SGLT inhibitors were reviewed in this paper. The number of SGLT inhibitor related patent applications in China, as well as the applicants, technology fields and important companies were analyzed. The strength and weakness in patent teclmology were compared between foreign and domestic applicants, so as to provide reference for further development of SGLT inhibitors.
出处
《药学进展》
CAS
2017年第11期852-856,共5页
Progress in Pharmaceutical Sciences
